I have a question for you guys. Would you have prefered if Berger had done a similar deal for Ponatinib as the one with Merck for Rida? The offering just might have been the best option at this point in time. Put yourself in his shoes for a minute. I am not a fan of Berger but I find myself annoyed at all the griping lately.
News 
Market Data 
Discover 
